Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cevimeline
Drug ID BADD_D00424
Description Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Indications and Usage For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Marketing Status approved
ATC Code N07AX03
DrugBank ID DB00185
KEGG ID D07667
MeSH ID C059240
PubChem ID 2684
TTD Drug ID D0Q4CS
NDC Product Code 64642-011; 63304-479
UNII K9V0CDQ56E
Synonyms cevimeline | 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | AF 102B, (trans)-isomer | AF-102B | AF 102B | AF102B | Evoxac | FKS 508 | FKS-508 | SNI 2011 | SNI-2011 | AF 102B, (cis-(+))-isomer | cevimeline hydrochloride
Chemical Information
Molecular Formula C10H17NOS
CAS Registry Number 124620-88-8
SMILES CC1OC2(CN3CCC2CC3)CS1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine abnormality20.02.01.013--Not Available
Urine flow decreased20.02.02.012--Not Available
Urogenital disorder21.10.05.010; 20.08.01.002--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection21.14.02.002; 11.01.10.002--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Visual impairment06.02.10.013--Not Available
Vitreous detachment12.01.04.005; 06.09.01.002--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Xerophthalmia14.12.03.002; 06.06.03.008--Not Available
Yawning22.12.03.037--Not Available
Multiple sclerosis relapse17.16.01.003--Not Available
Musculoskeletal disorder15.03.05.025--Not Available
Hypoacusis04.02.01.006--
Deep vein thrombosis24.01.02.003--Not Available
Post procedural haemorrhage12.02.05.004; 24.07.01.014--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Thermal burn23.03.11.042; 12.05.04.001--
The 13th Page    First    Pre   13 14 15    Next   Last    Total 15 Pages